Key facts
- It has raised $13.9M; the latest was Early Stage VC ($13.9M) in Jul 2025.
- Notable investors include Legend Capital, Lapam Capital, Unity Ventures (China), Hangzhou Qinglan Junke Equity Investment, Jiangsu Winfast Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Defand Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Defand Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Defand Therapeutics
Developer of biologically derived therapeutic solutions intended for medical research and experimental development. The company offers advanced biomedical R&D capabilities, cross-border technology exchange, and import-export operations, enabling the global healthcare market to accelerate drug discovery, enhance innovation pipelines, and expand access to novel treatment modalities through scalable and collaborative scientific infrastructure.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2023
- Website
- defandtx.com/
- Ownership
- Privately Held (backing)
Defand Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Defand Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Defand Therapeutics in its N-PORT filings yet. We sweep new filings monthly.